Drug intelligence / Profile preview

Rezyme

Development stage: Unknown
Lead developer: Ritz Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

Rezyme is an oral digestive enzyme supplement developed and marketed by Ritz Pharma, primarily indicated for the management of digestive disorders and flatulence. The formulation typically consists of fungal diastase and pepsin. Fungal diastase is an amylolytic enzyme that assists in the digestion of starch and complex carbohydrates, while pepsin is a proteolytic enzyme that aids in the breakdown of dietary proteins into smaller peptides. By supplementing endogenous digestive enzymes, Rezyme facilitates more efficient nutrient absorption and alleviates symptoms of dyspepsia, bloating, and intestinal gas. It is currently marketed in tablet form.

Brand names: Rezyme
Other names: Rezyme Tab.

Targets

Dietary proteins and peptide bonds

Beyond the preview

Go deeper on Rezyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rezyme.

Explore the full profile